ESSA Pharma Finalizes $80M Capital Distribution Amid Business Wind-up and Acquisition by XenoTherapeutics
ESSA Pharma Inc. has completed an $80 million cash distribution as part of its winding-up process following its acquisition by XenoTherapeutics, Inc. As of August 25, 2025, ESSA’s common shares began trading on an “ex-dividend” basis on Nasdaq, with a distribution of approximately $1.6910318 per share to shareholders on August 22. This marks a significant step in the discontinuation of ESSA’s business operations as XenoTherapeutics acquires all outstanding common shares.
ESSA Pharma Inc. has announced the completion of a cash distribution as part of its winding-up process following its transaction with XenoTherapeutics, Inc. As of August 25, 2025, ESSA’s common shares began trading on an “ex-dividend” basis on Nasdaq, following a distribution of approximately $1.6910318 per share to shareholders on August 22. This marks a significant step in the discontinuation of ESSA’s business operations, as XenoTherapeutics acquires all outstanding common shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on August 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
